JPRN-UMIN000016870已完成未知
Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization - Intravitreal tPA and ranibizumab for type 2 choroidal neovascularization
agoya City University Graduate School of Medicine0 个研究点目标入组 20 人开始时间: 2015年3月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •eyes with previous photodynamic therapy, medication for glaucoma, diabetic retinopathy, epiretinal membrane, vitreomacular traction, or high myopia (-6.0 diopters or worse)
研究者
相似试验
已完成
不适用
Combination therapy of intravitreal aflibercept and topical bromfenac for RVOretinal vein occlusionJPRN-UMIN000022988Juntendo Urayasu Hospital40
招募中
不适用
vitreous surgery with intravitreal tissue plasminogen activator(t-PA)globe ruptureJPRN-UMIN000015282Okayama University Hospital30
尚未招募
不适用
Effect of Alternate Treatment with Intravitreal Anti-Vascular Endothelial Growth Factor and Corticosteroid for Macular EdemaKCT0007766Hallym University Medical Center-Kangnam188
已完成
不适用
Intravitreal injection of anti vascular endothelial growth factor agent, Lucentis (ranibizumab), for the treatment of retinopathy of prematurityretinopathy of prematurityJPRN-UMIN000013975agoya University hospital ophtalmoligy30
进行中（未招募）
2 期
sing panitumumab with ranibizumab injected into the eye to treat exudative age-related macular degeneratioExudative age-related macular degenerationEye DiseasesISRCTN85022211fa Eye Research Institute200